Pain

Unsilenced Voices' Free Domestic Violence Community Event in Vegas

Retrieved on: 
Tuesday, May 10, 2022
Linda, Hope, Communal violence, Rayco Rodríguez, Blanket, Pain, Shade tree, Sexual assault, Survival, Public relations, Education, Survivor, Domestic violence, CEO, UV, Casino, Sex industry

LAS VEGAS, May 10, 2022 /PRNewswire/ -- Global domestic violence nonprofit Unsilenced Voices (UV) and RayCo Media (RayCo) proudly present A Blanket of Hope: Survivor to Thriver, a free community luncheon in Las Vegas Monday, May 23. UV will bring immediate assistance to abuse survivors; educate the public on building safer communities; and invite fellow organizations to collaborate through volunteerism, donation, or sponsorship.

Key Points: 
  • Global nonprofit brings direct help for abuse victims and education for community groups in Las Vegas Monday, May 23
    LAS VEGAS, May 10, 2022 /PRNewswire/ -- Global domestic violence nonprofit Unsilenced Voices (UV) and RayCo Media (RayCo) proudly present A Blanket of Hope: Survivor to Thriver, a free community luncheon in Las Vegas Monday, May 23.
  • "We're so grateful to our generous corporate sponsors and local partners for helping us end the pain and suffering brought by domestic abuse", says Jewsbury.
  • "We hope survivors in Las Vegas will come out and bravely choose the path to liberation."
  • Las Vegas is the second stop along UV's national tour, followed by Los Angeles, Tampa, and Montclair, NJ.

Study Finds That Wondr Program Improves Energy, Mood, Sleep and More

Retrieved on: 
Tuesday, May 10, 2022
Newton, Sleep, Population, Pain, Woman, Health, GLOBE, Lists of diseases, Doctor of Philosophy, Program, Quality of life, MPH, Association, Weight loss, Mental health, Solution, Risk management, DALLAS, MD

Physical benefits associated with weight loss are well-documented, but less is known about the effect on quality of life, said Tim Church, MD, MPH, PhD, Chief Medical Officer, Wondr Health.

Key Points: 
  • Physical benefits associated with weight loss are well-documented, but less is known about the effect on quality of life, said Tim Church, MD, MPH, PhD, Chief Medical Officer, Wondr Health.
  • This study evaluated 26,658 participants (79% women) after the initial 10 weeks of the Wondr program.
  • The purpose of this study was to examine the association between weight loss, change in physical activity, and quality of life following participation in the Wondr program.
  • Kim Newton is among the Wondr participants who saw positive improvements in her quality of life from this whole-person approach.

From Personal Tragedy to Opportunity for Thousands of Children with Disabilities

Retrieved on: 
Tuesday, May 10, 2022
Hope, Globe, University, Pain, Dream, Hand, United Nations, Confusion, Family, Profile, First Nations in Ontario, Government, Disability, Association, Achievement, Solution, Shalva, Sign language, Multimedia, Online shopping, Culture

NEW YORK, May 10, 2022 /PRNewswire/ -- Kalman Samuels left his university studies at the University of British Columbia to study in France between semesters; little did he know that he would not return to the University of British Columbia following his summer vacation, yet would eventually receive honorary doctorates and fellowships for his outstanding contributions to disability care and inclusion. Kalman's son, Yossi was injured as a result of a faulty medical procedure and was rendered blind and deaf among other disabilities at the age of eleven months. After traveling the world in search of diagnoses and solutions, Yossi experienced a miraculous breakthrough at the age of eight when he brilliantly learned to communicate using sign language in the palm of the hand. Inspired by their son's remarkable achievement, Kalman and his wife Malki set out on a journey to help other children and families coping with disability by establishing Shalva, an Israel-based non-profit organization.

Key Points: 
  • Kalman's son, Yossi was injured as a result of a faulty medical procedure and was rendered blind and deaf among other disabilities at the age of eleven months.
  • After traveling the world in search of diagnoses and solutions, Yossi experienced a miraculous breakthrough at the age of eight when he brilliantly learned to communicate using sign language in the palm of the hand.
  • Inspired by their son's remarkable achievement, Kalman and his wife Malki set out on a journey to help other children and families coping with disability by establishing Shalva, an Israel-based non-profit organization.
  • "The hundreds of young volunteers in the association represent a young generation and the values dedicated to grace and giving.

Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

Retrieved on: 
Tuesday, May 10, 2022
Tetra, COO, Forward-looking statement, Pain, True north, Insurance, Absorption, Company, Safety, Physician, Legislation, CFO, Patient, Doctor of Philosophy, FRA, FDA, Inflammation, Arbutus Biopharma, CCO, View, Chronic pain, TSX, Plasma protein binding, Terminology, Technology, Research, News, TBP, Multimedia, Generic drug, Pharmaceutical industry, CBD

OTTAWA, ON, May 10, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.

Key Points: 
  • OTTAWA, ON, May 10, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary liposome encapsulated technology within formulations distributed under the True North brand.
  • Tetra's patented technology leads to better absorption and aqueous emulsification of the CBD molecule in a variety of products.
  • "True North is pleased to have entered into a licensing agreement with Panag Pharma Inc. to exclusively incorporate their molecular technology into product formulations distributed under the True North brand.
  • Panag's patented CBD encapsulation technology is expected to further differentiate True North's branded product offering in the highly competitive medical and recreational CBD product market.

Bunion Treatment Takes a Leap Forward: New, No-Fusion Active Bunion Surgery is Simple, Fast & Improves on Other Options

Retrieved on: 
Tuesday, May 10, 2022
People, Disorder, Scar, Pain, Woman, Wrist, Physician, Injury, Time, Elbow, Patient, Hand, Commercial, Bunion, Ligament, Foot, Movement, Joint, Surgeon, Tendon, Extremities, Ankle, 3D printing, Health insurance, Veterinary medicine, Dentistry, Lapidus

Bunions are a familiar problem -- almost a quarter of adults ages 18-65 and a third over 65, mostly women, suffer from bunions on one or both feet1. Painful and even embarrassing, surgery can be a permanent solution for moderate to severe cases.

Key Points: 
  • Now, new Active Bunion surgery brings what we all want from modern medical care: the simplest possible remedy, done as a minimally invasive surgery that's fast and leaves a very minimal scar.
  • Active Bunion surgery delivers significant advances over traditional bunion surgery by restoring the foot's natural alignment in multiple dimensions, while avoiding any impact to the big toe joint.
  • And unlike the modernized Lapidus bunion procedure introduced a few years ago, Active Bunion surgery does not require fusing of any joints.
  • Fast recovery -- With no fusion or intrusion into the joint space, Active Bunion surgery can get people back on their feet more quickly.

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

Retrieved on: 
Tuesday, May 10, 2022
Epilepsy, NEW, Fragile X syndrome, The Michael J. Fox Foundation, Annual report, International Conference on Emerging Infectious Diseases, SIGMAR1, SEC, Program, Central nervous system, Mission statement, Pain, Twitter, Patient, FDA, Dementia, Degenerative disease, LinkedIn, Research, Nature, Instagram, Mouse, Central nervous system disease, IRSF, Webcast, BOI, Rett syndrome, FTD, Lists of diseases, Autism, GLOBE, CNS, Government budget balance, Amyloid, PDD, Doctor of Philosophy, Trial of the century, Cancer, Conference call, Therapy, Neurodegeneration, Adult, Precision medicine, EDGAR, Conference, Pharmaceutical industry, Medical device, Lithium, Diagnosis of schizophrenia, Facebook

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2022.

Key Points: 
  • ANAVEX2-73 Program and other Near-Term Pipeline Data Updates:
    Top-line results from the randomized, placebo-controlled Phase 2b/3 study ANAVEX2-73-AD-004 for the treatment of Alzheimers disease are expected 2H 2022.
  • Top-line results from the randomized, placebo-controlled EXCELLENCE Phase 2/3 study ANAVEX2-73-RS-003 for the treatment of pediatric patients with Rett syndrome are expected 2H 2022.
  • ANAVEX will host a R&D Day for investors and analysts on Tuesday, June 21, 2022.
  • Anavexs R&D Day will include presentations from the Companys leadership team with a focus on the Companys clinical development pipeline.

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Mutation, GAAP, Multiple myeloma, National Cancer Institute, Safety, Lymphoid leukemia, Ageing, SEC, Nausea, Pain, EZH2, Company, Private Securities Litigation Reform Act, Lists of diseases, NCCN, Patient, SETD2, FDA, SG, Workforce, Follicular lymphoma, Disease, B-cell lymphoma, Constipation, Epithelioid sarcoma, Vomiting, Methylation, Medicare, RNA, Fatigue, Upper respiratory tract infection, Neoplasm, Medicare Part D, Physician, Time, Bristol Myers Squibb, DNA, Sale, MM, RNA splicing, Journal of the National Comprehensive Cancer Network, Arm, COVID-19, Appetite, Nasdaq, Celgene, Form, DLBCL, Depreciation, Abdominal pain, Review, Webcast, Adult, Cancer, Form 10-K, Lymphoma, Society, ID, B cell, Pharmaceutical industry, Medical device, Video game, Lithium, Bank, Kerosene

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported first quarter 2022 financial results and provided a business update.

Key Points: 
  • Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported first quarter 2022 financial results and provided a business update.
  • Commercial demand increased 16% in the first quarter of 2022 versus the fourth quarter of 2021 levels while total demand (commercial demand and free goods supplied through the patient assistance program) in the first quarter of 2022 was similar to fourth quarter 2021 levels.
  • Epizyme, in collaboration with LYSA, anticipates presenting top-line results from the Phase 2 portion of the study in the second half of 2022.
  • Non-GAAP adjusted R&D expenses were $27.8 million for the first quarter of 2022, compared to $30.3 million for the first quarter of 2021.

AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, Syringe, Nasdaq, PCA, Ephedrine, Company, Pain, Patient, Webcast, Medication, Adult, Sufentanil, Acute respiratory distress syndrome, Investor, SST, Phenylephrine, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Multimedia, Pharmaceutical industry, Online shopping

HAYWARD, Calif., May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results before market open on Monday, May 16, 2022. AcelRx management will host a live webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on May 16, 2022 to discuss the financial results and provide an update on the company's business.

Key Points: 
  • HAYWARD, Calif., May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results before market open on Monday, May 16, 2022.
  • AcelRx management will host a live webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on May 16, 2022 to discuss the financial results and provide an update on the company's business.
  • The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.
  • A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com .

SI-BONE, Inc. Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
COVID-19, U.S. Securities and Exchange Commission, Pain, Nasdaq, NASDAQ, GLOBE, ASC, Company, Travel, Form, SI, Physician, Patient, Security (finance), Operating cost, Webcast, FDA, International, Risk, Lists of diseases, CMS, Form 10-K, Leadership, Publication, Marketing, Anatomy, Surgeon, SEC, Solution, Technology, Research, Growth, All rights reserved, Natural borrowing limit, Video game, Pharmaceutical industry

SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2022.
  • Worldwide revenue was $22.4 million in the first quarter 2022, a 10% increase from $20.4 million in the corresponding period in 2021.U.S.
  • Gross margin was 87% for the first quarter 2022, as compared to 89% in the corresponding period in 2021.
  • SI-BONE will host a conference call to discuss the first quarter 2022 financial results after market close on Monday, May 9, 2022 at 4:30 P.M. Eastern Time.

Mimo Monitors Returns to Integrated Systems Europe (in Booth #6-K620) in Barcelona After Pandemic Hiatus

Retrieved on: 
Monday, May 9, 2022
ISE, Emergency, Pain, HDMI, Tablet, Health, Fortune 500, Software, LINK, Verifone, Human, Common Alerting Protocol, Partnership, POP, Sale, Mark (given name), Education, Android, Solution, USB, Transport, Hertz, Multimedia, Nightclub, Mobile phone, Google, Ethernet, MIMO

CHICAGO, May 9, 2022 /PRNewswire/ -- Mimo Monitors, the global experts in small touchscreen displays and tablets, are thrilled to be announcing their return to Integrated Systems Europe (ISE) after a two-year hiatus due to the pandemic. This year, they'll be showcasing a vast variety of their product portfolio ranging from the revolutionary Mimo Myst Family to exclusive sneak peeks at new, announced software and hardware products. Mimo Monitors works in a wide array of verticals including conference rooms, digital signage, healthcare, education, interactive, transportation, and more.

Key Points: 
  • Mimo Monitors to showcase wide range of diverse product portfolio including the revolutionary Mimo Myst Family, sneak peek of new unannounced software, new product previews and more
    CHICAGO, May 9, 2022 /PRNewswire/ -- Mimo Monitors , the global experts in small touchscreen displays and tablets, are thrilled to be announcing their return to Integrated Systems Europe (ISE) after a two-year hiatus due to the pandemic.
  • This year, they'll be showcasing a vast variety of their product portfolio ranging from the revolutionary Mimo Myst Family to exclusive sneak peeks at new, announced software and hardware products.
  • Mimo Monitors works in a wide array of verticals including conference rooms, digital signage, healthcare, education, interactive, transportation, and more.
  • "ISE is a great show for us and we're looking forward to being back and connecting with many of our customers in person," said David Anderson, President of Mimo Monitors.